Comorbidities in spondyloarthropathies
Authors:
K. Pavelka
Authors‘ workplace:
Revmatologický ústav Praha
Published in:
Čes. Revmatol., 24, 2016, No. 4, p. 162-167.
Category:
Review Article
Overview
Comorbidity is a term that was first used to refer to other diseases that occur simultaneously with autoimmune rheumatic disorders. Its importance lies in the fact that comorbidities occur more often than in the general population or have more severe disease course or may relate to treatment of the underlying disease.
The author deals with the issue of comorbidity in spondyloarthritis (SpA). The most important comorbidities in SpA are: cardiovascular disease, kidney disease, lung disease, infection, malignancy, osteoporosis, gastrointestinal disorders and depression. Multicentre, international study ASAS COMOSPA examined the incidence of comorbidities in SpA and in the general population. The most commonly diagnosed comorbidity was osteoporosis (13.4%) and peptic ulcer (10.7%). The most common risk factors for cardiovascular disease included hypertension (33.5%), smoking (30%) and hypercholesterolemia (27%). Of the risk factors for cancer the most common one was family history of cervical cancer (15%). European league against rheumatism (EULAR) issued a document, which is titled "Points to Consider" when reporting, screening and preventing selected comorbidities in chronic, inflammatory, rheumatic diseases in daily practice. Recommendations are divided into three parent principles and a total of 15 points are defined as points for consideration. They are divided into six sections: cardiovascular disease, malignancies, infections, peptic ulcer disease, osteoporotic fractures, and depression. The role of a rheumatologist should not be in the examination of these comorbidities, but in coordination of these findings and cooperation of the entire team providing comprehensive care of the patient.
Key words:
Comorbidities, spondyloarthritis, EULAR
Sources
1. Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis 2016; 75 (6): 965–73.
2. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377: (9783): 2127–37.
3. Prati C, Claudepierre P, Pham T, et al. Mortality in spondylarthritis. J Bone Spine Rev Rheum 2011; 78: (5): 466–70.
4. Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am 2015; 41(4): 677–698.
5. Molto A, Atcheto A, van der Heide D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross –sectional ASAS. COMOSPA study. Ann Rheum Dis 2016; 75(6):1016–1023.
6. Salaffi F, Carotti M, Gasparini S, et al. The health – related quality of life in rheumatoid arthritis: a comparison with selected sample of healthy people. Health Qual Life Outcomes 2009;7: 25.
7. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21(5): 885–906.
8. Spaetgens B, Wihnands MA, van Durme C, et al. Content and construct validity of the Rheumatic Diseases Comorbidity index in patients with gout. Rheumatology 2015; 54(9): 1569–1663.
9. Nurmohamed MT, et al. EULAR recommendations update on cardiovascular disease in RA. Abstrakt. Ann Rheum Dis 2015; 74(Suppl. 2): 9.
10. Mosca M, Tani C, Ariger M, et al. EULAR recommendations for monitoring patients with SLE in clinical practise and observational studies. Ann rheum Dis 2010; 69(7): 1269–74.
11. Dougados M, Soubnier M, Perrodeu E, et al. Impact of a nurse – led programme on comorbidity management impact of a patient self. Assessment of disease activity on the management of RA: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann Rheum Dis 2015; 74(9): 1725–33.
12. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nature Reviews Rheumatology 2015; 11(12): 693–703.
13. Vencovský J. Bezpečnost biologické léčby. Doporučení České revmatologické společnosti. Čes Revmatol 2009; 17(3): 146–160.
14. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum (Arthritis Care & Research) 2008; 59(6): 762–784.
15. Pavelka K, Moster E, Ptáčková H. Očkování pacientů s revmatickými onemocněními v České republice. Acta Med 2013; 2(5): 9–12.
16. Kroon F, Landewe R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71(10): 1623–9.
17. Geusaens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007; 19(4): 335–339.
18. Pavelka K. Osteoporóza u spondyloartritid. Osteologický bulletin 2010; 15(2): 51–6.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2016 Issue 4
Most read in this issue
- Recommendations for the treatment of psoriatic arthritis
- Validation of a screening questionnaire for the presence of neuropsychiatric symptoms in patients with systemic lupus erythematosus in clinical practice
- Comorbidities in spondyloarthropathies